SPRC
SciSparc Ltd (SPRC)
Healthcare • NASDAQ • $5.87-15.25%
- Symbol
- SPRC
- Exchange
- NASDAQ
- Sector
- Healthcare
- Industry
- Biotechnology
- Price
- $5.87
- Daily Change
- -15.25%
- Market Cap
- $4.25M
- Trailing P/E
- 0.08
- Forward P/E
- N/A
- 52W High
- $80.10
- 52W Low
- $2.98
- Analyst Target
- N/A
- Dividend Yield
- N/A
- Beta
- 2.43
SciSparc Ltd., a clinical-stage pharmaceutical company, develops drugs based on cannabinoid therapies. Its drug development programs include SCI-110 for the treatment of Tourette syndrome and Alzheimer's disease and agitation; SCI-210 for the treatment of autism spectrum disorder and status epilepticus; and CannAmide, an anti-inflammatory and chronic pain solution. The company sells hemp seed oil-based products and others. The company has an agreement with Procaps to develop and commercially manufacture SCI-110 and palmitoylethanolamide oral tablets CannAmide in softgel capsule form. It also has an agreement with The Israeli Medical Center for Alzheimer's to conduct a phase IIa clinical trial to evaluate the safety, tolerability, and efficacy of SCI-110 in patients with Alzheimer's disease…
Company websiteResearch SPRC on Stk-Ai
Stk-Ai gives you screening across 100+ fundamental metrics, AI-powered analysis, target predictions, backtested signals, and portfolio tracking — all in one place.
Data shown is for informational purposes only and is not investment advice. Prices and metrics may be delayed.